

(19)



(11)

EP 2 330 420 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
06.09.2017 Bulletin 2017/36

(51) Int Cl.:
G01N 33/564 ^(2006.01) **G01N 33/68** ^(2006.01)
G01N 33/53 ^(2006.01)

(21) Application number: **09809743.9**

(86) International application number:
PCT/JP2009/063633

(22) Date of filing: **31.07.2009**

(87) International publication number:
WO 2010/024089 (04.03.2010 Gazette 2010/09)

(54) **DIAGNOSIS METHOD AND DIAGNOSIS KIT FOR CLINICAL AMYOPATHIC DERMATOMYOSITIS**

DIAGNOSEVERFAHREN UND DIAGNOSEKIT FÜR KLINISCHE AMYOPATHISCHE DERMATOMYOSITIS

PROCÉDÉ DE DIAGNOSTIC ET KIT DE DIAGNOSTIC POUR LA DERMATOMYOSITE AMYOPATHIQUE CLINIQUE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

(30) Priority: **01.09.2008 JP 2008223789**

(43) Date of publication of application:
08.06.2011 Bulletin 2011/23

(73) Proprietor: **Keio University**
Tokyo 108-8345 (JP)

(72) Inventors:
 • **KUWANA, Masataka**
Tokyo 160-8582 (JP)
 • **SATO, Shinji**
Tokyo 160-8582 (JP)
 • **FUJITA, Takashi**
Kyoto-shi
Kyoto 606-8507 (JP)

(74) Representative: **Müller-Boré & Partner**
Patentanwälte PartG mbB
Friedenheimer Brücke 21
80639 München (DE)

(56) References cited:
WO-A2-2005/016962 US-A- 6 160 107

- **SHINJI SATO ET AL: "RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease", ARTHRITIS & RHEUMATISM, vol. 60, no. 7, 1 July 2009 (2009-07-01), pages 2193-2200, XP55003397, ISSN: 0004-3591, DOI: 10.1002/art.24621**
- **SATO S ET AL. ARTHRITIS RHEUM. vol. 52, no. 5, May 2005, pages 1571 - 1576, XP055003396**
- **MICHITO HIRAKATA JAPANESE JOURNAL OF CHINICAL IMMUNOLOGY vol. 30, no. 6, 2007, pages 444 - 454, XP008144413**
- **SHINJI SATO MOLECULAR RHEUMATOLOGY vol. 3, no. 1, 2006, pages 3 - 8, XP008144818**
- **YAMASAKI Y ET AL. ARTHRITIS RHEUM. vol. 56, no. 2, February 2007, pages 596 - 604, XP008144817**
- **VILLERS A ET AL. ANN DERMATOL VENEREOL. vol. 133, no. 6-7, July 2006, pages 573 - 576, XP008144394**
- **YOSHIRO HORAI ET AL: "Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases", MODERN RHEUMATOLOGY ; OFFICIAL JOURNAL OF THE JAPAN COLLEGE OF RHEUMATOLOGY, SPRINGER-VERLAG, TO, vol. 23, no. 1, 30 March 2012 (2012-03-30) , pages 190-194, XP035162400, Spinger Inc Tokyo ISSN: 1439-7609, DOI: 10.1007/S10165-012-0637-6**

EP 2 330 420 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- M. J. FRITZLER ET AL: "Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 178, no. 1, 1 July 1993 (1993-07-01), pages 49-62, XP55176177, Rockefeller University Press, New York NY USA ISSN: 0022-1007, DOI: 10.1084/jem.178.1.49
- H. KATO ET AL: "Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses", NATURE, vol. 441, no. 7089, 9 April 2006 (2006-04-09), pages 101-105, XP055094652, Basingstoke UK ISSN: 0028-0836, DOI: 10.1038/nature04734
- S. MOGHADAM-KIA ET AL.: "Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis", ARTHRITIS CARE & RESEARCH, vol. 68, no. 5, 1 May 2016 (2016-05-01), pages 689-694, Hoboken NJ USA
- D-TEK: "MDA-5", 1 October 2015 (2015-10-01), D-TEK, Mons BE, XP55289407, pages 1-2,
- MOISES LABRADOR-HORILLO ET AL: "Anti-MDA5 Antibodies in a Large Mediterranean Population of Adults with Dermatomyositis", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2014, ID 29079, 4 February 2014 (2014-02-04), pages 1-8, XP55289406, Cairo

Description

[0001] The present invention relates to a method and the use of a kit for diagnosing clinically amyopathic dermatomyositis, and use of an antigenic protein for diagnosing clinically amyopathic dermatomyositis.

[0002] A basic characteristic of connective tissue disease that causes it to be regarded as an autoimmune disease is the production of autoantibodies against various cellular components. It is known that many of the antigens corresponding to such autoantibodies are enzymes and regulatory factors that are essential to life processes. Investigating the molecular structures of the autoantibodies and antigens corresponding thereto (autoantigens), and their biological functions is expected to contribute to the elucidation of the pathogenesis of connective tissue diseases.

[0003] Polymyositis/dermatomyositis (PM/DM) is an inflammatory myopathy in which proximal muscle weakness and muscular pain caused by skeletal muscle inflammation predominate. Particularly, when typical skin symptoms such as heliotrope rash and Gottron's papules are observed, the patient is diagnosed with DM. Polymyositis/dermatomyositis is one of the autoimmune diseases, and various autoantibodies are known to develop. The presence of antibodies in the sera of PM/DM patients has been reported; such antibodies include anti-aminoacyl tRNA synthetase antibody (anti-ARS antibody), anti-SRP antibody, anti-Mi-2 antibody, and like antibodies specifically detected in myositis patients, as well as anti-U1RNP antibody, anti-SS-A antibody, and like autoantibodies associated with myositis. It is known that patients who are positive for the same myositis-specific autoantibody exhibit similar clinical characteristics; this is clinically useful for diagnosis, classification of disease types, selection of appropriate treatment methods, and estimation of prognosis.

[0004] In contrast, autoantibody negativity was considered to be one of the characteristics of clinically amyopathic DM (C-ADM), which is a sub-type of PM/DM. The presence of autoantibodies specific to C-ADM was unknown. It was known that C-ADM is resistant to clinical treatment and associated with poor prognostic rapidly progressive interstitial lung disease (RP-ILD). To save the life of C-ADM patients with RP-ILD, the efficacy of potent treatment from an early stage using a combination of high dose steroid therapy and immunosuppressive drug administration has been reported and recommended. For this reason, early diagnosis of C-ADM with associated RP-ILD is clinically important, and the establishment of new indicators that are useful for early diagnosis has been desired.

[0005] In light of the above background, the present inventors investigated the sera of normal healthy controls, those of patients with connective tissue diseases including C-ADM, and those of patients with idiopathic pulmonary fibrosis, according to an immunoprecipitation (IPP) method. The inventors found that a new autoantibody capable of recognizing a 140-kDa protein is present in the sera of C-ADM patients, and termed the new autoantibody "anti-CADM-140 antibody" (Non-Patent Literature 1 (NPL 1)).

[0006] The anti-CADM-140 antibody was not detected in any of the patients with connective tissue diseases other than C-ADM, patients with idiopathic pulmonary fibrosis (IPF), and normal healthy controls. Clinically, significantly frequent development of RP-ILD in anti-CADM-140 antibody-positive patients was observed, which suggests a correlation between the anti-CADM-140 antibody and RP-ILD (Non-Patent Document 2).

[0007] This phenomenon is considered to be useful for early diagnosis and treatment selection for extremely poor prognostic C-ADM with associated RP-ILD, and is thus expected to improve its prognosis.

[0008] MDA5 has a SNP (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?locusId=64135). The amino acid sequence and the base sequence thereof are available under NCBI Accession Number NM_022168. Patent Literature 1 (PTL 1) discloses the relationship between MDA5 and cancer.

[0009] The present inventors published Non-Patent Literature 3 (NPL 3), which discloses the closest prior art. Departing from NPL3, the present invention provides methods and usages of kits for the early diagnosis of C-ADM, which are more amenable to large scale applications than the method of NPL3 and which do not require the use of radio-labelled components as does the method of NPL3.

Citation List

Patent Literature

[0010]

PTL 1: Japanese Unexamined Patent Document No. 2003-531581 (Fisher, P.B. et al.; the Trustees of Columbia University in the City of New York)

PTL 2: US-patent 6,160,107 (Targoff, I. N. et al.; Oklahoma Medical Research Foundation) describes nucleic acids encoding antigens associated with polymyositis and dermatomyositis.

Non-patent Literature

[0011]

NPL 1: Shinji Sato, Akira Suwa, Takaki Nojima, Misako Suzuki, Yuko Kaneko, Masataka Kuwana, Shinichi Inada, Nasashi Akizuki, Takeji Nishikawa, Michito Hirakata; Clinical and Immunological Features of Autoantibodies of the 140 kDa Polypeptide in Patients with Amyopathic Dermatomyositis; *Arthritis Rheum.* 46(9): S398, 2002.

5 NPL 2: Shinji Sato, Michito Hirakata, Masataka Kuwana, Akira Suwa, Shinichi Inada, Tsuneyo Mimori, Takeji Nishikawa, Chester V. Oddis, and Yasuo Ikeda; Autoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients With Clinically Amyopathic Dermatomyositis; *Arthritis Rheum.* 52(5): 1571-1576, 2005.

NPL 3: Shinji Sato, Kana Hoshino, Takashi Satoh, Tomonobu Fujita, Yutaka Kawakami, Takashi Fujita, and Masataka Kuwana; RNA Helicase Encoded by Melanoma Differentiation-Associated Gene 5 Is a Major Autoantigen in Patients With Clinically Amyopathic Dermatomyositis: Association with Rapidly Progressive Interstitial Lung Disease; *Arthritis Rheum.* 60(7): 2193-2200, 2009.

10 NPL 4: Michito Hirakata; *Jpn. J. Clin. Immunol.*, 30(6), 444-454, 2007, describes autoantibodies and their clinical significance in idiopathic inflammatory myopathies; polymyositis/dermatomyositis and related conditions.

NPL 5: Shinji Sato; *Molecular Rheumatology*, vol. 3, no. 1, 2006, 3-8, describes novel antibodies in polymyositis/dermatomyositis;

15 NPL 6: Yamasaki Y. et al.; *Arthritis Rheum.* 56(2): 596-604, 2007, describes autoantibodies to RNA helicase A.

NPL 7: Villers A. et al.; *Ann. Dermatol. Venereol.*, 133(6-7), 573-576, 2006, describes regression of primary melanoma with metastases associated with amyopathic dermatomyositis.

20 **[0012]** Further, document Sato (Sato, S.; *Molecular Rheumatology*, 3(1); 2006; pp. 3-8) describes novel antibodies in the diagnosis of polymyositis and dermatomyositis. Document Fritzler *et al.* (Fritzler, M. J. et al.; *Journal of Experimental Medicine*, 178(1); 1993; pp. 49-62) describes the molecular characterization of human autoantigens encoded by unique cDNAs encoding 95 and 160 kDa proteins of a putative family in the Golgi complex. Kato *et al.* (Kato, H. et al.; *Nature*, 441(7089); 2006; pp. 101-105) describes differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.

25 Further, WO 2005/016962 A2 describes protein-containing compositions and methods of using the same for the diagnosis and treatment of immune related diseases such as idiopathic inflammatory myopathies. Furthermore, Horai *et al.*; *Modern Rheumatology*, 23(1); 2012; pp. 190-194) describes two cases of an early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease. Moreover, document "D-tek: MDA5" describes a kit comprising MDA5 for the detection of antibodies directed against the same. Finally, Labrador-Horillo *et al.* (Labrador-Horillo, M. et al.; *Journal of Immunology Research*; 2014; pp. 1-8) describes anti-MDA5 antibodies in a large mediterranean population of adults with dermatomyositis.

30 **[0013]** In NPL3 anti-CADM-140 antibody has been generally measured according to an IPP method using S³⁵-labeled leukemia-derived K562 cell extracts or HeLa cells. Although this is a reliable measurement method with high sensitivity and high specificity, the method utilizes isotopes and requires complicated procedures. Accordingly, the measurement method has been used only in a limited number of laboratories.

35 **[0014]** To apply anti-CADM-140 antibody measurement to actual clinical diagnosis, it is necessary to establish a measurement system that enables easy measurement of large quantities of samples. Identification of an antigen corresponding to anti-CADM-140 antibody, preparation of a recombinant protein, and establishment of a measurement system by ELISA etc., are important to establish such a system.

40 **[0015]** The present inventors used a HeLa cell cDNA library to clone an antigen gene corresponding to anti-CADM-140 antibody, and investigated the molecular sequence of the corresponding antigen protein. As a result, the inventors found that MDA5 (Melanoma Differentiation Associated Gene 5) is an antigen corresponding to anti-CADM-140 antibody and have accomplished the present invention based on this finding.

[0016] The present invention provides uses of kits and methods for diagnosing clinically amyopathic dermatomyositis according to the appended claims.

45 **[0017]** According to the present invention, extremely poor prognostic clinically amyopathic dermatomyositis associated with a high risk for developing extremely poor prognostic rapidly progressive interstitial lung disease can be detected with high accuracy.

[0018] The present invention enables quick measurement of anti-CADM-140 antibody in many samples. This is useful for early diagnosis and treatment selection for C-ADM with associated RP-ILD, and is expected to improve the prognosis of this disease whose treatment method has not been established and which has been considered as an extremely poor prognostic disease. Furthermore, the accumulation of anti-CADM-140 antibody-positive samples will enable the analysis of foreign antigens, such as a virus that is the target of a specific autoantibody, and contribute to the elucidation of the pathogenesis of C-ADM with associated RP-ILD.

50 **[0019]** The figures show:

[FIG. 1] FIG. 1 shows the results of investigation of a reaction between a protein of Clone #8 (MDA5) as an antigen and the sera of C-ADM patients according to an immunoprecipitation method, which was performed after purifying the protein of Clone #8 (MDA5) and confirming the expression of the protein using an in vitro transcription/translation

system. The Clone #8 (MDA5) reacted with all of the anti-CADM-140 antibody-positive serum samples, but it did not react with the sera of normal healthy controls.

[FIG. 2] FIG. 2 shows the results of investigation of a reaction between a recombinant protein of Clone #8 (MDA5) as an antigen, and the sera of anti-CADM-140 antibody-positive C-ADM patients, those of patients with other connective tissue diseases, and those of normal healthy controls, according to an immunoprecipitation method, which was performed after purifying the protein of Clone #8 (MDA5) and confirming expression of the protein using an in vitro transcription/translation system. The recombinant protein did not react with the sera of normal healthy controls or the sera of patients other than anti-CADM-140 antibody-positive C-ADM patients.

[FIG. 3] FIG. 3 shows the IPP-IB results. When anti-CADM-140 antibody was reacted with an MDA5-expressing African green monkey renal cell-derived COS7 cell extract, the resulting 140-kDa immunoprecipitate reacted with goat anti-MDA5 antibody.

[FIG. 4] FIG. 4 shows the immunoblotting results of the sera of anti-CADM-140 antibody-positive patients and those of normal healthy controls, obtained by using recombinant RIG-I, recombinant MDA5, and recombinant LGP-2 as antigens. The sera of anti-CADM-140 antibody-positive patients reacted only with the recombinant MDA5, whereas the sera of normal healthy controls (NHC) did not react at all.

[FIG. 5] FIG. 5 shows the ELISA results of the sera of anti-CADM-140 antibody-positive C-ADM patients, those of anti-CADM-140 antibody-negative C-ADM patients, those of PM/DM patients, those of scleroderma (SSc) patients, those of systemic lupus erythematosus (SLE) patients, those of ILD patients, and those of normal healthy controls, obtained by using MDA5 as an antigen substrate. The cutoff value is indicated by a horizontal line. The analytical sensitivity and analytical specificity of this ELISA system were 85% and 100%, respectively.

[0020] A feature of the present invention is an antigen (MDA5) specifically recognized by anti-CADM-140 antibody, which was found by the present inventor. MDA5 is one type of RIG-I family protein. RIG-I family proteins participate in a specific immune response that includes interferon type I production. RIG-I family proteins are highly homologous and contain a DexD/H-box helicase domain. In addition to MDA5, RIG-I and LPG-2 are also known as RIG-I family proteins. These proteins are very similar in sequence and structure, and are thus likely to be cross-reactive. Accordingly, the reactivity between anti-CADM-140 antibody and RIG-I family proteins was also investigated. The binding of anti-CADM-140 antibody to MDA5 depends on the conformation of the antigen, and anti-CADM-140 antibody preferentially reacts with an MDA5 partially modified from its native structure. These factors made it difficult to determine that anti-CADM-140 antibody is an antibody to MDA5.

[0021] To identify anti-CADM-140 antibody, the present inventors purified an antigen protein corresponding thereto and tried to identify the antigen protein by mass spectrometry. However, it was impossible to purify a sufficient amount of the antigen protein, and identification was difficult. This was considered to be attributable to low amounts of antigen in the serum or to the affinity of the antigen-antibody reaction.

[0022] Further, in the early stages of C-ADM, it is difficult to distinguish the disease from other types of dermatomyositis, because C-ADM is difficult to diagnose and requires follow-up to carefully determine whether muscular symptoms are present or not.

[0023] However, the present inventors identified MDA5 specifically recognized by anti-CADM-140 antibody. As a result, it became clear that the clinical sensitivity and clinical specificity of the ELISA assay of dermatomyositis (C-ADM) are 69% and 99.6%, respectively. Although anti-CADM-140 antibody-positive C-ADM patients were previously difficult to diagnose or the diagnosis often took much time, the present invention enables quick diagnosis.

[0024] In this specification, "dermatomyositis" includes clinically amyopathic dermatomyositis (C-ADM), which is a subtype of DM, but does not include polymyositis PM. Thus, the present invention provides a kit and a method for diagnosing whether the subject has C-ADM or other diseases. DM is an inflammatory myopathy in which characteristic skin symptoms such as heliotrope rash and Gottron's papules, and proximal muscle weakness and/or muscular pain caused by skeletal muscle inflammation predominate. DM is generally diagnosed according to the diagnostic criteria of Bohan & Peter (Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med 1975; 292: 344). However, C-ADM, which refers to the case in which cutaneous lesions characteristic of DM are exhibited but muscle weakness is not exhibited, does not meet the criteria of Bohan & Peter, and has been undiagnosable. In 2002, Sontheimer proposed new classification criteria in which a case of typical skin lesions without muscle weakness is called "C-ADM" (clinically amyopathic dermatomyositis), and "C-ADM" is classified as a subtype of DM [Sontheimer RD: Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002; 46: 626-36]. The target DM to be diagnosed according to the present invention includes those that meet the classification criteria of Sontheimer.

[0025] The diagnostic kit used in the present invention and the diagnostic method of the present invention use an MDA5 protein or a fragment thereof recognized by anti-CADM-140 antibody to detect anti-CADM-140 antibody (hereinafter the "fragment recognized by anti-CADM-140 antibody" is sometimes simply referred to as an "immunogenic peptide"). Since the C-terminal 523-amino-acid sequence fragment (SEQ ID NO: 2) of MDA5 protein shown in SEQ ID

NO: 4 binds to anti-CADM-140 antibody, an epitope recognized by anti-CADM-140 antibody is present in the C-terminal region of MDA5 protein. Insofar as this epitope is maintained, the MDA5 protein or the immunogenic peptide thereof generally may be a modified MDA5 protein or immunogenic peptide thereof that has one or more amino acid deletions, substitutions, additions, or insertions in a non-epitopic region thereof. The epitope typically consists of about 5 to about 10 amino acids, and particularly about 5 to about 8 amino acids. For example, the epitope of MDA5 can be determined by synthesizing a specific number of peptides (for example, 10 peptides at a time) while shifting by a fixed number of amino acids (for example, 5 amino acids) from the N-terminus of the C-terminal fragment of MDA5 shown in SEQ ID NO: 2 (for example, prepare a peptide consisting of the first to tenth amino acids, a peptide consisting of the sixth to 15th amino acids, a peptide consisting of the 11th to 20th amino acids, a peptide consisting of the 16th to 25th amino acids, ...), and then investigating the reactivity of each of the peptide fragments with anti-CADM-140 antibody. When the epitope is determined or the location of the epitope is narrowed down, the MDA5 protein (immunogenic peptide) fragment recognized by anti-CADM-140 antibody can be shortened. Generally, a shorter immunogenic peptide is preferable from the viewpoint of ease of production. A peptide consisting of 40 or less amino acids, 30 or less amino acids, or 20 or less amino acids, particularly about 5 to about 10 amino acids, is preferable. RNA helicase is encoded by MDA5.

[0026] MDA5 is known to have an SNP. SEQ ID NO: 3 represents a base sequence of MDA5. SEQ ID NO: 1 represents a base sequence encoding a C-terminal fragment of the MDA5 fragment shown in SEQ ID NO: 2. However, the MDA5 of other amino acid sequences/base sequences that are related by SNP, or alleles of MDA5 are also included in the scope of "MDA5" in this specification.

[0027] The MDA5 or the immunogenic peptide used in the present invention is expressed as a recombinant protein and produced by genetic engineering, or is produced by chemical synthesis. Generally, when the immunogenic peptide has a short sequence consisting of preferably 50 or less amino acids, more preferably 30 or less, even more preferably 20 or less, and particularly, 5 to 10 amino acids, chemical synthesis (a solid or liquid phase synthesis) is preferably used to produce the peptide. The MDA5 or the immunogenic peptide thereof may be used in the form of a monomer, and may be crosslinked by a polyfunctional crosslinking agent such as glutaraldehyde, or can be produced by genetic engineering by using DNA encoding a peptide in which immunogenic peptides are connected in tandem.

[0028] The anti-CADM-140 antibody may be obtained from any sample such as the blood, serum, plasma, cerebrospinal fluid, and lymph of a subject. Blood, serum, and plasma are preferable, and serum is particularly preferable as the sample.

[0029] The kit used in diagnosing dermatomyositis according to the present invention contains an MDA5 protein or an immunogenic peptide thereof. The kit may contain a substance for detecting an antigen-antibody complex of an MDA5 protein or an immunogenic peptide thereof, and anti-CADM-140 antibody. Examples of such substances include anti-human immunoglobulin antibodies that are labeled with peroxidases such as horseradish peroxidase (HRP), enzyme labels such as β -galactosidase, alkaline phosphatase, and luciferase, fluorescent labels such as FITC (fluorescein isothiocyanate) and RITC (tetramethylrhodamin isothiocyanate), or any other suitable labels, and particularly anti-human IgG antibodies labeled therewith.

[0030] Immunoassay is preferably used for the diagnostic kit used in the present invention and the diagnostic method of the present invention. Examples of the immunoassay include enzyme immunoassay (EIA), ELISA, fluoroimmunoassay (FIA), chemiluminescent immunoassay, immunoblotting (IB), Western blotting, immunostaining, and like methods.

[0031] The MDA5 protein or the immunogenic peptide used in the present invention is preferably bonded to a solid phase. Examples of such solid phases include agarose, wells of a microtiter plate, latex particles, and the like. Specific examples of the ELISA method include competitive immunoassay, sandwich immunoassay, and the like.

[0032] According to the method for diagnosing dermatomyositis of the present invention, a sample obtained from a subject is brought into contact with an MDA5 protein shown in SEQ ID NO: 4 or an immunogenic peptide thereof to detect the presence or absence of an antigen-antibody complex of MDA5 or an immunogenic peptide thereof and anti-CADM-140 antibody by a physical or chemical method.

[0033] The method for diagnosing dermatomyositis of the present invention comprises the steps as defined in item 5. above.

[0034] The diagnostic kit used in the present invention may contain:

- (i) an antigen comprising an MDA5 protein shown in SEQ ID NO: 4 or an immunogenic peptide thereof (the antigen may be adhered to wells of a microtiter plate etc., and may further be blocked with a blocking agent such as skim milk, or an albumin such as bovine serum albumin (BSA) or I) ;
- (ii) a medium suitable for the reaction between a sample of a subject and the antigen (i) (for example, buffers such as PBS);
- (iii) a reagent for detecting a complex of the antigen (i) and anti-CADM-140 antibody (for example, a labeled anti-human immunoglobulin antibody that can bind to anti-CADM-140 antibody); and optionally
- (iv) a reference sample not containing anti-CADM-140 antibody.

[0035] The "reference sample not containing anti-CADM-140 antibody" includes, for example, blood, serum, and

plasma samples of normal healthy controls.

[0036] When the anti-human immunoglobulin antibody is labeled with peroxidase, anti-CADM-140 antibody can be detected by a process comprising adding a color development substrate such as tetramethylbenzidine; stopping the reaction with H₂SO₄; and measuring absorbance (450 nm: OD₄₅₀) using a plate reader.

[0037] By testing many samples using the diagnostic kit according to the present invention and comparing the obtained results with other clinical observations, more accurate criteria for determining whether a subject has clinically amyopathic DM, based on the measured amount of anti-CADM-140 antibody can be established.

Examples

[0038] The present invention is described below in more detail.

Example 1: Method for early diagnosis of C-ADM

[0039] An antigenic protein was expressed in *E. coli* by using an *E. coli* (XL1-Blue MRF) expressing lambda ZAP phage prepared by using a HeLa cell cDNA library. The expressed protein was transferred to a nitrocellulose membrane, and reacted with anti-CADM-140 antibody-positive serum to isolate positive clones. Next, the reactivity of the obtained positive clones with 10 serum samples of anti-CADM-140 antibody-positive C-ADM patients, 14 serum samples of anti-CADM-140 antibody-negative persons (two C-ADM samples, two PM samples, one sample each of systemic lupus erythematosus, scleroderma, and interstitial lung disease, and seven samples of normal healthy controls) was investigated. Among the 9 clones that were obtained, Clone #8 reacted with anti-CADM-140 antibody-positive serum samples at high frequency, i.e. 9 out of 10 anti-CADM-140 antibody-positive C-ADM serum samples. After the protein was purified and expression was confirmed using an in vitro transcription/translation assay, the reactivity of the sera of C-ADM patients with the protein as an antigen was investigated by immunoprecipitation. Clone #8 reacted with all of the anti-CADM-140 antibody-positive serum samples, but did not react with the sera of normal healthy controls (FIG. 1). Further, Clone #8 did not react with the sera of patients with connective tissue diseases other than anti-CADM-140 antibody-positive C-ADM (FIG. 2). Further, to determine the base sequence of Clone #8, plasmid DNA was excised from phage DNA from which the clone was obtained. The plasmid DNA was purified to determine the base sequence. Finally, a homology search was performed for the obtained base sequence, and the sequence was perfectly matched to the C-terminal sequence of MDA5.

[0040] An anti-CADM-140 antibody-positive serum was reacted with an MDA5-expressing African green monkey renal cell-derived COS7 cell extract by the IPP-IB method. The reactivity of 140 kDa of the obtained immunoprecipitate with goat anti-MDA5 antibody was investigated. When MDA5 was expressed, the immunoprecipitate reacted with goat anti-MDA5 antibody (FIG. 3). Further, the reactivity of anti-CADM-140 antibody-positive sera and the sera of normal healthy controls with recombinant purified proteins of RIG-I family RIG-I, MD5, and LGP-2 as antigens was investigated. The sera of anti-CADM-140 antibody-positive patients reacted only with recombinant MDA5, whereas the sera of normal healthy controls did not react with recombinant MDA5 (FIG. 4). It became clear from the above results that the antigen corresponding to anti-CADM-140 antibody is MDA5.

[0041] Further, the present inventors coated a 96-well plate with purified recombinant MDA5 as an antigen to establish an ELISA for an anti-CADM-140 antibody assay. The diagnostic sensitivity and diagnostic specificity of the anti-CADM-140 antibody assay method were investigated.

[0042] More specifically, recombinant MDA5 was immobilized on a 96-well ELISA plate in an amount of 0.05 μg/well and blocked with 3% BSA. Serum samples (each 250-fold diluted) were dispensed to the plate in an amount of 100 μl per well, and allowed to react at room temperature for 2 hours. As a secondary antibody, 5000-fold diluted peroxidase conjugated goat anti-human-IgG was used. Tetramethylbenzidine (1 mg/ml) was added as a color development substrate, and the reaction was stopped with H₂SO₄. The absorbance was measured with a plate reader (450 nm: OD₄₅₀). Using this assay system, the serum samples of C-ADM-containing collagen disease patients, those of interstitial lung disease (ILD) patients, and those of normal healthy controls were measured. The results showed that the reactivity of the sera of the anti-CADM-140 antibody-positive PM/DM patients was higher than that of the anti-CADM-140 antibody-negative PM/DM patients, scleroderma (SSc) patients, systemic lupus erythematosus (SLE) patients, ILD patients, and normal healthy controls (FIG. 5). When the average + up to 10 times the standard deviation of normal healthy controls was defined as the normal cutoff range, the analytical sensitivity and the analytical specificity measured by this ELISA assay system were 85% and 100%, respectively. Thus, the results clearly show that this assay is an anti-CADM-140 antibody detection method with excellent sensitivity and specificity.

SEQUENCE LISTING

[0043]

EP 2 330 420 B1

<110> KEIO UNIVERSITY

<120> The diagnostic product for dermatomyositis

5 <130> P09-69

<150> JP 2008-223789

<151> 2008-9-1

10 <160> 4

<170> PatentIn version 3.4

<210> 1

15 <211> 1706

<212> DNA

<213> Homo sapiens

<400> 1

20

gaagaacaca ttttaaaact atgtgccaat cttgatgcat ttactattaa aactgttaaa 60

gaaaaccttg atcaactgaa aaaccaaata caggagccat gcaagaagtt tgccattgca 120

25 gatgcaacca gagaagatcc atttaaagag aaacttctag aaataatgac aaggattcaa 180

acttattgtc aaatgagtcc aatgtcagat tttggaactc aaccctatga acaatgggcc 240

attcaaatgg aaaaaaaaaagc tgcaaaaagaa ggaaatcgca aagaacgtgt ttgtgcagaa 300

30 catttgagga agtacaatga ggccctacaa attaatgaca caattcgaat gatagatgcg 360

tatactcatc ttgaaacttt ctataatgaa gagaaagata agaagtttgc agtcatagaa 420

35 gatgatagtg atgaggggtg tgatgatgag tattgtgatg gtgatgaaga tgaggatgat 480

ttaaagaaac ctttgaaact ggatgaaaca gatagatttc tcatgacttt attttttgaa 540

aacaataaaa tgttgaaaag gctggctgaa aaccagaat atgaaaatga aaagctgacc 600

40 aaattaagaa ataccataat ggagcaatat actaggactg aggaatcagc acgaggaata 660

atctttacaa aaacacgaca gagtgcatat gcgctttccc agtggattac tgaaaatgaa 720

45 aaatttgctg aagtaggagt caaagcccac catctgattg gagctggaca cagcagtgag 780

ttcaaaccce tgacacagaa tgaacaaaaa gaagtcatta gtaaatttcg cactggaaaa 840

ataaatctgc ttatcgctac cacagtggca gaagaaggtc tggatattaa agaatgtaac 900

50 attgttatcc gttatggtct cgtcaccaat gaaatagcca tgggccaggc cctggtcga 960

gccagagctg atgagagcac ctacgtcctg gttgctcaca gtggttcagg agttatcga 1020

catgagacag ttaatgatth cagagagaag atgatgtata aagctataca ttgtgttcaa 1080

55 aatatgaaac cagaggagta tgctcataag attttggaaat tacagatgca aagtataatg 1140

gaaaagaaaa tgaaaaccaa gagaaatatt gccaagcatt acaagaataa cccatcacta 1200

EP 2 330 420 B1

ataactttcc tttgcaaaaa ctgcagtgtg ctagcctggt ctggggaaga tatccatgta 1260
 attgagaaaa tgcatacacgt caatatgacc ccagaattca aggaacttta cattgtaaga 1320
 5 gaaaacaaag cactgcaaaa gaagtgtgcc gactatcaaa taaatggtga aatcatctgc 1380
 aaatgtggcc aggcttgggg aacaatgatg gtgcacaaa gcttagattt gccttgtctc 1440
 10 aaaataagga atttttagt ggttttcaaa aataattcaa caagaaaca atacaaaaag 1500
 tgggtagaat tacctatcac atttcccaat cttgactatt cagaatgctg tttatttagt 1560
 gatgaggatt agcacttgat tgaagattct tttaaaatac tatcagttaa acatttaata 1620
 15 tgattatgat taatgtattc attatgctac agaactgaca taagaatcaa taaaatgatt 1680
 gttttactct gcaaaaaaaaa aaaaaa 1706

<210> 2

20 <211> 523

<212> PRT

<213> Homo sapiens

25 <400> 2

Glu Glu His Ile Leu Lys Leu Cys Ala Asn Leu Asp Ala Phe Thr Ile
 1 5 10 15
 30 Lys Thr Val Lys Glu Asn Leu Asp Gln Leu Lys Asn Gln Ile Gln Glu
 20 25 30
 35 Pro Cys Lys Lys Phe Ala Ile Ala Asp Ala Thr Arg Glu Asp Pro Phe
 35 40 45
 40 Lys Glu Lys Leu Leu Glu Ile Met Thr Arg Ile Gln Thr Tyr Cys Gln
 50 55 60
 45 Met Ser Pro Met Ser Asp Phe Gly Thr Gln Pro Tyr Glu Gln Trp Ala
 65 70 75 80
 50 Ile Gln Met Glu Lys Lys Ala Ala Lys Glu Gly Asn Arg Lys Glu Arg
 85 90 95
 55 Val Cys Ala Glu His Leu Arg Lys Tyr Asn Glu Ala Leu Gln Ile Asn
 100 105 110
 Asp Thr Ile Arg Met Ile Asp Ala Tyr Thr His Leu Glu Thr Phe Tyr
 115 120 125
 Asn Glu Glu Lys Asp Lys Lys Phe Ala Val Ile Glu Asp Asp Ser Asp
 130 135 140

EP 2 330 420 B1

Glu Gly Gly Asp Asp Glu Tyr Cys Asp Gly Asp Glu Asp Glu Asp Asp
 145 150 155 160
 5
 Leu Lys Lys Pro Leu Lys Leu Asp Glu Thr Asp Arg Phe Leu Met Thr
 165 170 175
 10
 Leu Phe Phe Glu Asn Asn Lys Met Leu Lys Arg Leu Ala Glu Asn Pro
 180 185 190
 15
 Glu Tyr Glu Asn Glu Lys Leu Thr Lys Leu Arg Asn Thr Ile Met Glu
 195 200 205
 20
 Gln Tyr Thr Arg Thr Glu Glu Ser Ala Arg Gly Ile Ile Phe Thr Lys
 210 215 220
 25
 Thr Arg Gln Ser Ala Tyr Ala Leu Ser Gln Trp Ile Thr Glu Asn Glu
 225 230 235 240
 30
 Lys Phe Ala Glu Val Gly Val Lys Ala His His Leu Ile Gly Ala Gly
 245 250 255
 35
 His Ser Ser Glu Phe Lys Pro Met Thr Gln Asn Glu Gln Lys Glu Val
 260 265 270
 40
 Ile Ser Lys Phe Arg Thr Gly Lys Ile Asn Leu Leu Ile Ala Thr Thr
 275 280 285
 45
 Val Ala Glu Glu Gly Leu Asp Ile Lys Glu Cys Asn Ile Val Ile Arg
 290 295 300
 50
 Tyr Gly Leu Val Thr Asn Glu Ile Ala Met Val Gln Ala Arg Gly Arg
 305 310 315 320
 55
 Ala Arg Ala Asp Glu Ser Thr Tyr Val Leu Val Ala His Ser Gly Ser
 325 330 335
 Gly Val Ile Glu His Glu Thr Val Asn Asp Phe Arg Glu Lys Met Met
 340 345 350
 Tyr Lys Ala Ile His Cys Val Gln Asn Met Lys Pro Glu Glu Tyr Ala
 355 360 365
 His Lys Ile Leu Glu Leu Gln Met Gln Ser Ile Met Glu Lys Lys Met
 370 375 380

EP 2 330 420 B1

Lys Thr Lys Arg Asn Ile Ala Lys His Tyr Lys Asn Asn Pro Ser Leu
 385 390 395 400
 5
 Ile Thr Phe Leu Cys Lys Asn Cys Ser Val Leu Ala Cys Ser Gly Glu
 405 410 415
 10
 Asp Ile His Val Ile Glu Lys Met His His Val Asn Met Thr Pro Glu
 420 425 430
 15
 Phe Lys Glu Leu Tyr Ile Val Arg Glu Asn Lys Ala Leu Gln Lys Lys
 435 440 445
 20
 Cys Ala Asp Tyr Gln Ile Asn Gly Glu Ile Ile Cys Lys Cys Gly Gln
 450 455 460
 25
 Ala Trp Gly Thr Met Met Val His Lys Gly Leu Asp Leu Pro Cys Leu
 465 470 475 480
 30
 Lys Ile Arg Asn Phe Val Val Val Phe Lys Asn Asn Ser Thr Lys Lys
 485 490 495
 Gln Tyr Lys Lys Trp Val Glu Leu Pro Ile Thr Phe Pro Asn Leu Asp
 500 505 510
 35
 Tyr Ser Glu Cys Cys Leu Phe Ser Asp Glu Asp
 515 520
 40
 <210> 3
 <211> 3434
 <212> DNA
 <213> Homo sapiens
 45
 50
 55
 <400> 3

EP 2 330 420 B1

gccccgctgc ccacctgccc gcctgcccac ctgcccaggt gcgagtgcag ccccgcgcgc 60
cggcctgaga gccctgtgga caacctcgtc attgtcaggc acagagcggg agaccctgct 120
5 tctctaagtg ggcagcggac agcggcacgc acatttcacc tgtcccgcag acaacagcac 180
catctgcttg ggagaaccct ctcccttctc tgagaaagaa agatgtcgaa tgggtattcc 240
acagacgaga atttccgcta tctcatctcg tgcttcaggg ccagggtgaa aatgtacatc 300
10 caggtggagc ctgtgctgga ctacctgacc tttctgctg cagaggtgaa ggagcagatt 360
cagaggacag tcgccacctc cgggaacatg caggcagttg aactgctgct gaggaccttg 420
15 gagaagggag tctggcacct tggttggact cgggaattcg tggaggccct ccggagaacc 480
ggcagccctc tggccgcccg ctacatgaac cctgagctca cggacttgcc ctctccatcg 540
20 tttgagaacg ctcatgatga atatctccaa ctgctgaacc tccttcagcc cactctggtg 600

25

30

35

40

45

50

55

EP 2 330 420 B1

gacaagcttc tagttagaga cgtcttggat aagtgcattgg aggaggaact gttgacaatt 660
 gaagacagaa accggattgc tgctgcagaa aacaatggaa atgaatcagg tgtaagagag 720
 5 ctactaaaaa ggattgtgca gaaagaaaac tggttctctg ctttctgaa tgttcttcgt 780
 caaacaggaa acaatgaact tgtccaagag ttaacaggct ctgattgctc agaaagcaat 840
 gcagagattg agaatttatc acaagttgat ggtcctcaag tggaaagagca acttctttca 900
 10 accacagttc agccaaatct ggagaaggag gtctggggca tggagaataa ctcatcagaa 960
 tcatcttttg cagattcttc tgtagtttca gaatcagaca caagtttggc agaaggaagt 1020
 gtcagctgct tagatgaaag tcttggacat aacagcaaca tgggcagtga ttcaggcacc 1080
 15 atgggaagtg attcagatga agagaatgtg gcagcaagag catccccgga gccagaactc 1140
 cagctcaggc cttaccaaact ggaagttgcc cagccagcct tggaaagggaa gaatatcatc 1200
 20 atctgcctcc ctacaggag tggaaaaacc agagtggctg tttacattgc caaggatcac 1260
 ttagacaaga agaaaaagc atctgagcct ggaaaagtta tagttcttgt caataaggta 1320
 ctgctagtgt aacagctctt ccgcaaggag ttccaacat ttttgaagaa atggtatcgt 1380
 25 gttattggat taagtgggtga tacccaactg aaaatatcat ttccagaagt tgtcaagtcc 1440
 tgtgatatta ttatcagtac agctcaaact cttgaaaact ccctcttaa cttggaaaat 1500
 30 ggagaagatg ctggtgttca attgtcagac tttccctca ttatcattga tgaatgtcat 1560
 cacaccaaca aagaagcagt gtataataac atcatgaggc attatttgat gcagaagttg 1620
 aaaaacaata gactcaagaa agaaaacaaa ccagtgattc cccttctca gatactggga 1680
 35 ctaacagctt cacctgggtg tggaggggac acgaagcaag ccaaagctga agaacacatt 1740
 ttaaaactat gtgccaatct tgatgcattt actattaata ctgttaaaga aaaccttgat 1800
 caactgaaaa accaaataca ggagccatgc aagaagtttg ccattgcaga tgcaaccaga 1860
 40 gaagatccat ttaaagagaa acttctagaa ataatgacaa ggattcaaac ttattgtcaa 1920
 atgagtccaa tgtcagattt tggaaactca ccctatgaac aatgggcat tcaaatggaa 1980
 45 aaaaaagctg caaaagaagg aaatcgcaaa gaacgtgttt gtgcagaaca tttgaggaag 2040
 tacaatgagg ccctacaaat taatgacaca attcgaatga tagatgcgta tactcatctt 2100
 gaaactttct ataatgaaga gaaagataag aagtttgcag tcatagaaga tgatagtgat 2160
 50 gagggtggtg atgatgagta ttgtgatggt gatgaagatg aggatgattt aaagaaacct 2220
 ttgaaactgg atgaaacaga tagatttctc atgactttat tttttgaaaa caataaaatg 2280
 ttgaaaaggc tggctgaaaa cccagaatat gaaaatgaaa agctgaccaa attaaagaaat 2340
 55 accataatgg agcaatatac taggactgag gaatcagcac gaggaataat ctttacaaaa 2400

EP 2 330 420 B1

	acacgacaga gtgcatatgc gctttcccag tggattactg aaaatgaaaa atttgctgaa	2460
	gtaggagtca aagcccacca tctgattgga gctggacaca gcagtgagtt caaacccatg	2520
5	acacagaatg aacaaaaaga agtcattagt aaatttcgca ctggaaaaat aaatctgctt	2580
	atcgctacca cagtggcaga agaaggtctg gatattaaag aatgtaacat tgttatccgt	2640
10	tatggctctcg tcaccaatga aatagccatg gtccaggccc gtggtcgagc cagagctgat	2700
	gagagcacct acgtcctggg tgctcacagt ggttcaggag ttatcgaaca tgagacagtt	2760
	aatgatttcc gagagaagat gatgtataaa gctatacatt gtgttcaaaa tatgaaacca	2820
15	gaggagtatg ctcataagat tttggaatta cagatgcaaa gtataatgga aaagaaaatg	2880
	aaaaccaaga gaaatattgc caagcattac aagaataacc catcactaat aactttcctt	2940
	tgcaaaaact gcagtgtgct agcctgttct ggggaagata tccatgtaat tgagaaaatg	3000
20	catcacgtca atatgacccc agaattcaag gaactttaca ttgtaagaga aaacaaagca	3060
	ctgcaaaaaga agtgtgccga ctatcaaata aatggtgaaa tcatctgcaa atgtggccag	3120
25	gcttggggaa caatgatggt gcacaaaggc ttagatttgc cttgtctcaa aataaggaat	3180
	tttgtagtgg ttttcaaaaa taattcaaca aagaaacaat acaaaaagtg ggtagaatta	3240
	cctatcacat ttcccaatct tgactattca gaatgctggt tatttagtga tgaggattag	3300
30	cacttgattg aagattcttt taaaatacta tcagttaaac atttaatatg attatgatta	3360
	atgtattcat tatgctacag aactgacata agaatcaata aaatgattgt tttactctgc	3420
35	aaaaaaaaaa aaaa	3434
	<210> 4	
	<211> 1025	
	<212> PRT	
40	<213> Homo sapiens	
	<400> 4	
45		
50		
55		

EP 2 330 420 B1

Met Ser Asn Gly Tyr Ser Thr Asp Glu Asn Phe Arg Tyr Leu Ile Ser
1 5 10 15

5 Cys Phe Arg Ala Arg Val Lys Met Tyr Ile Gln Val Glu Pro Val Leu
20 25 30

10 Asp Tyr Leu Thr Phe Leu Pro Ala Glu Val Lys Glu Gln Ile Gln Arg
35 40 45

15 Thr Val Ala Thr Ser Gly Asn Met Gln Ala Val Glu Leu Leu Leu Ser
50 55 60

Thr Leu Glu Lys Gly Val Trp His Leu Gly Trp Thr Arg Glu Phe Val

20

25

30

35

40

45

50

55

EP 2 330 420 B1

Glu Gly Lys Asn Ile Ile Ile Cys Leu Pro Thr Gly Ser Gly Lys Thr
 325 330 335
 5 Arg Val Ala Val Tyr Ile Ala Lys Asp His Leu Asp Lys Lys Lys Lys
 340 345 350
 10 Ala Ser Glu Pro Gly Lys Val Ile Val Leu Val Asn Lys Val Leu Leu
 355 360 365
 15 Val Glu Gln Leu Phe Arg Lys Glu Phe Gln Pro Phe Leu Lys Lys Trp
 370 375 380
 Tyr Arg Val Ile Gly Leu Ser Gly Asp Thr Gln Leu Lys Ile Ser Phe
 385 390 395 400
 20 Pro Glu Val Val Lys Ser Cys Asp Ile Ile Ile Ser Thr Ala Gln Ile
 405 410 415
 25 Leu Glu Asn Ser Leu Leu Asn Leu Glu Asn Gly Glu Asp Ala Gly Val
 420 425 430
 30 Gln Leu Ser Asp Phe Ser Leu Ile Ile Ile Asp Glu Cys His His Thr
 435 440 445
 35 Asn Lys Glu Ala Val Tyr Asn Asn Ile Met Arg His Tyr Leu Met Gln
 450 455 460
 40 Lys Leu Lys Asn Asn Arg Leu Lys Lys Glu Asn Lys Pro Val Ile Pro
 465 470 475 480
 Leu Pro Gln Ile Leu Gly Leu Thr Ala Ser Pro Gly Val Gly Gly Ala
 485 490 495
 45 Thr Lys Gln Ala Lys Ala Glu Glu His Ile Leu Lys Leu Cys Ala Asn
 500 505 510
 50 Leu Asp Ala Phe Thr Ile Lys Thr Val Lys Glu Asn Leu Asp Gln Leu
 515 520 525
 Lys Asn Gln Ile Gln Glu Pro Cys Lys Lys Phe Ala Ile Ala Asp Ala
 530 535 540
 55 Thr Arg Glu Asp Pro Phe Lys Glu Lys Leu Leu Glu Ile Met Thr Arg
 545 550 555 560

EP 2 330 420 B1

Ile Gln Thr Tyr Cys Gln Met Ser Pro Met Ser Asp Phe Gly Thr Gln
565 570 575

5 Pro Tyr Glu Gln Trp Ala Ile Gln Met Glu Lys Lys Ala Ala Lys Glu
580 585 590

10 Gly Asn Arg Lys Glu Arg Val Cys Ala Glu His Leu Arg Lys Tyr Asn
595 600 605

15 Glu Ala Leu Gln Ile Asn Asp Thr Ile Arg Met Ile Asp Ala Tyr Thr
610 615 620

His Leu Glu Thr Phe Tyr Asn Glu Glu Lys Asp Lys Lys Phe Ala Val
625 630 635 640

20 Ile Glu Asp Asp Ser Asp Glu Gly Gly Asp Asp Glu Tyr Cys Asp Gly
645 650 655

25 Asp Glu Asp Glu Asp Asp Leu Lys Lys Pro Leu Lys Leu Asp Glu Thr
660 665 670

30 Asp Arg Phe Leu Met Thr Leu Phe Phe Glu Asn Asn Lys Met Leu Lys
675 680 685

35 Arg Leu Ala Glu Asn Pro Glu Tyr Glu Asn Glu Lys Leu Thr Lys Leu
690 695 700

Arg Asn Thr Ile Met Glu Gln Tyr Thr Arg Thr Glu Glu Ser Ala Arg
705 710 715 720

40 Gly Ile Ile Phe Thr Lys Thr Arg Gln Ser Ala Tyr Ala Leu Ser Gln
725 730 735

45 Trp Ile Thr Glu Asn Glu Lys Phe Ala Glu Val Gly Val Lys Ala His
740 745 750

His Leu Ile Gly Ala Gly His Ser Ser Glu Phe Lys Pro Met Thr Gln
755 760 765

50 Asn Glu Gln Lys Glu Val Ile Ser Lys Phe Arg Thr Gly Lys Ile Asn
770 775 780

55 Leu Leu Ile Ala Thr Thr Val Ala Glu Glu Gly Leu Asp Ile Lys Glu
785 790 795 800

EP 2 330 420 B1

Cys Asn Ile Val Ile Arg Tyr Gly Leu Val Thr Asn Glu Ile Ala Met
 805 810 815
 5 Val Gln Ala Arg Gly Arg Ala Arg Ala Asp Glu Ser Thr Tyr Val Leu
 820 825 830
 10 Val Ala His Ser Gly Ser Gly Val Ile Glu His Glu Thr Val Asn Asp
 835 840 845
 15 Phe Arg Glu Lys Met Met Tyr Lys Ala Ile His Cys Val Gln Asn Met
 850 855 860
 20 Lys Pro Glu Glu Tyr Ala His Lys Ile Leu Glu Leu Gln Met Gln Ser
 865 870 875
 25 Ile Met Glu Lys Lys Met Lys Thr Lys Arg Asn Ile Ala Lys His Tyr
 885 890 895
 30 Lys Asn Asn Pro Ser Leu Ile Thr Phe Leu Cys Lys Asn Cys Ser Val
 900 905 910
 35 Leu Ala Cys Ser Gly Glu Asp Ile His Val Ile Glu Lys Met His His
 915 920 925
 40 Val Asn Met Thr Pro Glu Phe Lys Glu Leu Tyr Ile Val Arg Glu Asn
 930 935 940
 45 Lys Ala Leu Gln Lys Lys Cys Ala Asp Tyr Gln Ile Asn Gly Glu Ile
 945 950 955 960
 50 Ile Cys Lys Cys Gly Gln Ala Trp Gly Thr Met Met Val His Lys Gly
 965 970 975
 55 Leu Asp Leu Pro Cys Leu Lys Ile Arg Asn Phe Val Val Val Phe Lys
 980 985 990
 60 Asn Asn Ser Thr Lys Lys Gln Tyr Lys Lys Trp Val Glu Leu Pro Ile
 995 1000 1005
 65 Thr Phe Pro Asn Leu Asp Tyr Ser Glu Cys Cys Leu Phe Ser Asp
 1010 1015 1020
 70 Glu Asp
 1025

Claims

- 5
1. Use of a kit for diagnosing clinically amyopathic dermatomyositis (C-ADM), the kit comprising the recombinant or chemically synthesized Melanoma Differentiation Associated Gene 5 (MDA5) protein consisting of SEQ ID NO: 4, or an MDA5 specific immunogenic peptide of said MDA5 protein, wherein said MDA5 specific immunogenic peptide of said MDA5 protein is a C-terminal fragment of the MDA5 protein, said fragment consisting of SEQ ID NO: 2.
 - 10 2. The use according to claim 1 of a kit according to claim 1 for diagnosing C-ADM associated with a high risk for developing rapidly progressive interstitial lung disease.
 - 15 3. The use according to claim 1 of a kit according to claim 1 for diagnosing C-ADM, wherein the kit is used for measurement by enzyme-linked immunosorbent assay (ELISA); wherein said MDA5 protein or said MDA5 specific immunogenic peptide of said MDA5 protein is bound to a solid phase.
 - 20 4. A method for diagnosing c-ADM, comprising allowing a sample of a subject to react with the recombinant or chemically synthesized MDA5 protein consisting of SEQ ID NO: 4, or an MDA5 specific immunogenic peptide of said MDA5 protein; and diagnosing the subject as having C-ADM when an antibody against said MDA5 protein or said MDA5 specific immunogenic peptide of said MDA5 protein consisting of SEQ ID NO: 2 is detected in the sample; wherein the sample is a blood, serum, or plasma sample.
 - 25 5. The method according to claim 4 wherein the antibody against said MDA5 protein or said MDA5 specific immunogenic peptide of said MDA5 protein in the sample is detected by ELISA, and wherein the method comprises the following steps:
 - (i) depositing a specific amount of the recombinant or chemically synthesized MDA5 protein consisting of SEQ ID NO: 4, or an MDA5 specific immunogenic peptide of said MDA5 protein consisting of SEQ ID NO: 2 on a plurality of wells of a microtiter plate;
 - (ii) diluting a sample of a subject suspected of having C-ADM, and adding the diluted sample to the wells;
 - 30 (iii) washing the microtiter plate after incubation;
 - (iv) introducing a labeled anti-human immunoglobulin antibody to the wells of the microtiter plate; and
 - (v) detecting the amount of label bound to the antibody by comparison with a control.
 - 35 6. Use of the recombinant or chemically synthesized Melanoma Differentiation Associated Gene 5 (MDA5) protein consisting of SEQ ID NO: 4, or an MDA5 specific immunogenic peptide of said MDA5 protein consisting of ID SEQ NO: 2 to diagnose clinically amyopathic dermatomyositis (C-ADM).

Patentansprüche

- 40
1. Verwendung eines Kits für die Diagnose klinisch amyopathischer Dermatomyositis (C-ADM), wobei der Kit das rekombinant oder chemisch synthetisierte *Melanoma Differentiation Associated Gene 5* (MDA5)-Protein, bestehend aus SEQ ID NO: 4, oder ein MDA5-spezifisches immunogenes Peptid des MDA5-Proteins umfaßt, wobei das MDA5-spezifische immunogene Peptid des MDA5-Proteins ein C-terminales Fragment des MDA5-Proteins ist, wobei das Fragment aus SEQ ID NO: 2 besteht.
 - 45 2. Verwendung nach Anspruch 1 eines Kits nach Anspruch 1 für die Diagnose von C-ADM, welche mit einem hohen Risiko für die Entwicklung von rasch fortschreitender interstitieller Lungenerkrankung verbunden ist.
 - 50 3. Verwendung nach Anspruch 1 eines Kits nach Anspruch 1 für die Diagnose von C-ADM, wobei der Kit für eine Messung mittels *enzyme-linked immunosorbent assay* (ELISA) verwendet wird, wobei das MDA5-Protein oder das MDA5-spezifische immunogene Peptid des MDA5-Proteins an eine feste Phase gebunden ist.
 - 55 4. Verfahren zur Diagnose von c-ADM, umfassend das Reagierenlassen einer Probe eines Subjekts mit dem rekombinant oder chemisch synthetisierten MDA5-Protein, bestehend aus SEQ ID NO: 4, oder einem MDA5-spezifischen immunogenen Peptid des MDA5-Proteins, und Diagnostizieren des Subjekts als C-ADM aufweisend, wenn ein Antikörper gegen das MDA5-Protein oder das MDA5-spezifische immunogene Peptid des MDA5-Proteins, beste-

EP 2 330 420 B1

hend aus SEQ ID NO: 2, in der Probe nachgewiesen wird,
wobei die Probe eine Blut-, Serum- oder Plasmaprobe ist.

- 5 5. Verfahren nach Anspruch 4, wobei der Antikörper gegen das MDA5-Protein oder das MDA5-spezifische immuno-
gene Peptid des MDA5-Proteins in der Probe mittels ELISA nachgewiesen wird und wobei das Verfahren die
folgenden Schritte umfasst:

- 10 (i) Ablegen einer spezifischen Menge des rekombinant oder synthetisch synthetisierten MDA5-Proteins, beste-
hend aus SEQ ID NO: 4, oder eines MDA5-spezifischen immunogenen Peptids des MDA5-Proteins, bestehend
aus SEQ ID NO: 2, in einer Vielzahl von Vertiefungen einer Mikrotiterplatte,
(ii) Verdünnen einer Probe eines Subjekts, das im Verdacht steht, C-ADM aufzuweisen, und Zugeben der
verdünnten Probe zu den Vertiefungen,
(iii) Waschen der Mikrotiterplatte nach Inkubation,
15 (iv) Einbringen eines markierten Antikörpers, der gegen humanes Immunglobulin gerichtet ist, in die Vertiefungen
der Mikrotiterplatte und
(v) Nachweisen der Menge der an den Antikörper gebundenen Markierung durch Vergleich mit einer Kontrolle.

- 20 6. Verwendung des rekombinant oder chemisch synthetisierten *Melanoma Differentiation Associated Gene 5*
(MDA5)-Proteins, bestehend aus SEQ ID NO: 4, oder eines MDA5-spezifischen immunogenen Peptids des MDA5-
Proteins, bestehend aus SEQ ID NO: 2, für die Diagnose klinisch amyopathischer Dermatomyositis (C-ADM).

Revendications

- 25 1. Utilisation d'un kit pour le diagnostic de la dermatomyosite cliniquement amyopathique (C-ADM), le kit comprenant
la protéine du gène 5 associé à la différenciation des mélanomes (MDA5) recombinante ou synthétisée chimiquement
constituée de SEQ ID NO : 4, ou un peptide immunogène spécifique de MDA5 de ladite protéine MDA5 dans lequel
ledit peptide immunogène spécifique de MDA5 de ladite protéine MDA5 est un fragment C-terminal de la protéine
30 MDA5, ledit fragment étant constitué de SEQ ID NO : 2.

3. Utilisation selon la revendication 1 d'un kit selon la revendication 1 pour le diagnostic de la C-ADM associée à un
risque élevé de développer rapidement une maladie pulmonaire interstitielle progressive.

- 35 3. Utilisation selon la revendication 1 d'un kit selon la revendication 1 pour le diagnostic de la C-ADM, dans laquelle
le kit est utilisé pour une mesure par la technique ELISA (enzyme-linked immunosorbent assay) ;
dans laquelle ladite protéine MDA5 ou ledit peptide immunogène spécifique de MDA5 de ladite protéine MDA5 est
lié à une phase solide.

- 40 4. Procédé de diagnostic de la C-ADM, comprenant l'étape permettant à un échantillon d'un sujet de réagir avec la
protéine MDA5 recombinante ou synthétisée chimiquement constituée de SEQ ID NO : 4, ou un peptide immunogène
spécifique de MDA5 de ladite protéine MDA5 ; et le diagnostic du sujet comme souffrant de C-ADM lorsqu'un
anticorps dirigé contre ladite protéine MDA5 ou ledit peptide immunogène spécifique de MDA5 de ladite protéine
MDA5 constitué de SEQ ID NO : 2 est détecté dans l'échantillon ;
dans lequel l'échantillon est un échantillon de sang, de sérum, ou de plasma.

- 45 5. Procédé selon la revendication 4 dans lequel l'anticorps dirigé contre ladite protéine MDA5 ou ledit peptide immu-
nogène spécifique de MDA5 de ladite protéine MDA5 dans l'échantillon est détecté par la technique ELISA, et dans
lequel le procédé comprend les étapes suivantes :

- 50 (i) le dépôt d'une quantité spécifique de la protéine MDA5 recombinante ou synthétisée chimiquement constituée
de SEQ ID NO : 4, ou d'un peptide immunogène spécifique de MDA5 de ladite protéine MDA5 constitué de
SEQ ID NO : 2 dans une pluralité de puits d'une plaque de microtitrage ;
(ii) la dilution d'un échantillon d'un sujet suspecté de souffrir de C-ADM, et l'addition de l'échantillon dilué aux
puits ;
55 (iii) le lavage de la plaque de microtitrage après incubation ;
(iv) l'introduction d'un anticorps anti-immunoglobuline humaine marqué dans les puits de la plaque de
microtitrage ; et
(v) la détection de la quantité de marqueur lié à l'anticorps par comparaison à un témoin.

EP 2 330 420 B1

6. Utilisation de la protéine du gène 5 associé à la différenciation des mélanomes (MDA5) recombinante ou synthétisée chimiquement constituée de SEQ ID NO : 4, ou d'un peptide immunogène spécifique de MDA5 de ladite protéine MDA5 constitué de SEQ ID NO : 2 pour diagnostiquer la dermatomyosite cliniquement amyopathique (C-ADM).

5

10

15

20

25

30

35

40

45

50

55

Fig. 1




Fig. 2




Fig. 3




Fig. 4





Fig. 5



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP 2003531581 A, Fisher, P.B. [0010]
- US 6160107 A, Targoff, I. N. [0010]
- WO 2005016962 A2 [0012]
- JP 2008223789 A [0043]

Non-patent literature cited in the description

- **SHINJI SATO ; AKIRA SUWA ; TAKAKI NOJIMA ; MISAKO SUZUKI ; YUKO KANEKO ; MASATAKA KUWANA ; SHINICHI INADA ; NASASHI AKIZUKI ; TAKEJI NISHIKAWA ; MICHITO HIRAKATA.** Clinical and Immunological Features of Autoantibodies of the 140 kDa Polypeptide in Patients with Amyopathic Dermatomyositis. *Arthritis Rheum.*, 2002, vol. 46 (9), S398 [0011]
- **SHINJI SATO ; MICHITO HIRAKATA ; MASATAKA KUWANA ; AKIRA SUWA ; SHINICHI INADA ; TSUNEYO MIMORI ; TAKEJI NISHIKAWA ; CHESTER V. ODDIS ; YASUO IKEDA.** Autoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients With Clinically Amyopathic Dermatomyositis. *Arthritis Rheum.*, 2005, vol. 52 (5), 1571-1576 [0011]
- **SHINJI SATO ; KANA HOSHINO ; TAKASHI SATOH ; TOMONOBU FUJITA ; YUTAKA KAWAKAMI ; TAKASHI FUJITA ; MASATAKA KUWANA.** RNA Helicase Encoded by Melanoma Differentiation-Associated Gene 5 Is a Major Autoantigen in Patients With Clinically Amyopathic Dermatomyositis: Association with Rapidly Progressive Interstitial Lung Disease. *Arthritis Rheum*, 2009, vol. 60 (7), 2193-2200 [0011]
- **MICHITO HIRAKATA.** *Jpn. J. Clin. Immunol.*, 2007, vol. 30 (6), 444-454 [0011]
- **SHINJI SATO.** *Molecular Rheumatology*, 2006, vol. 3 (1), 3-8 [0011]
- **YAMASAKI Y. et al.** *Arthritis Rheum.*, 2007, vol. 56 (2), 596-604 [0011]
- **VILLERS A. et al.** *Ann. Dermatol. Venereol.*, 2006, vol. 133 (6-7), 573-576 [0011]
- **SATO, S.** *Molecular Rheumatology*, 2006, vol. 3 (1), 3-8 [0012]
- **FRITZLER, M. et al.** *Journal of Experimental Medicine*, 1993, vol. 178 (1), 49-62 [0012]
- **KATO, H. et al.** *Nature*, 2006, vol. 441 (7089), 101-105 [0012]
- **HORAI et al.** *Modern Rheumatology*, 2012, vol. 23 (1), 190-194 [0012]
- **LABRADOR-HORILLO, M. et al.** *Journal of Immunology Research*, 2014, 1-8 [0012]
- **BOHAN A ; PETER JB.** Polymyositis and dermatomyositis. *N Engl J Med*, 1975, vol. 292, 344 [0024]
- **SONTHEIMER RD.** Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness?. *J Am Acad Dermatol*, 2002, vol. 46, 626-36 [0024]

专利名称(译)	临床肌病性皮肌炎的诊断方法和诊断试剂盒		
公开(公告)号	EP2330420B1	公开(公告)日	2017-09-06
申请号	EP2009809743	申请日	2009-07-31
[标]申请(专利权)人(译)	学校法人庆应义塾		
申请(专利权)人(译)	庆应大学		
当前申请(专利权)人(译)	庆应大学		
[标]发明人	KUWANA MASATAKA SATO SHINJI FUJITA TAKASHI		
发明人	KUWANA, MASATAKA SATO, SHINJI FUJITA, TAKASHI		
IPC分类号	G01N33/564 G01N33/68 G01N33/53		
CPC分类号	G01N33/5743 G01N33/6854		
优先权	2008223789 2008-09-01 JP		
其他公开文献	EP2330420A1 EP2330420A4		
外部链接	Espacenet		

摘要(译)

本发明的目的是鉴定对应于抗CADM-140抗体的抗原，产生重组蛋白，并通过ELISA等建立测定系统。本发明提供了用于诊断皮肌炎的试剂盒，其含有SEQ ID NO：4中所示的MDA5蛋白或其抗CDM-140抗体识别的片段。

```

gaagaacaca ttttaaaact atgtgccaat ctgtatgcat ttactattaa aactgttaaa 60
gaaaaccttg atcaactgaa aaaccacaata caggagccat gcaagaagtt tgccattgca 120
gatgcaacca gagaagatcc atttaaaagag aaacttctag aaataatgac aaggattcaa 180
acttattgtc aaatgagtcc aatgtcagat tttggaactc aaccctatga acaatgggcc 240
attcaaatgg aaaaaaaaagc tgcaaaaagaa ggaatcgca aagaacgtgt ttgtgcagaa 300
catttgagga agtacaatga ggcctacaa attaatgaca caatcgaat gatagatgag 360
tataactcctc ttgaaacttt ctataatgaa gagaaagata agaagtttgc agtcatagaa 420
gatgatagtg atgagggtgg tgatgatgag tattgtgatg gtgatgaaga tgaggatgat 480
ttaaagaaac ctttgaact ggatgaaaca gatagatttc tcatgacttt attttttgaa 540
aacaataaaa tgttgaaaag gctggctgaa aaccagaat atgaaaatga aaagctgacc 600
aaattaagaa ataccataat ggagcaatat actaggactg aggaatcagc acgaggaata 660
atctttacaa aaacacgaca gagtgcatat gcgctttccc agtggttac tgaaaatgaa 720
aaatttgctg aagtaggagt caaagcccc catctgattg gagctggaca cagcagtgag 780
ttcaaaccca tgacacagaa tgaacaaaa gaagtcatta gtaaatttcg cactggaaaa 840
ataaatctgc ttatcgtctc cacagtggca gaagaaggtc tggatattaa agaatgtaac 900
attgttatcc gttatggtct cgtaccaat gaaatagcca tggccaggc ccgtggctga 960
gccagagctg atgagagcac ctacgtcctg gttgctcaca gtggttcagg agttatcgaa 1020
catgagacag ttaatgatgt ccgagagaag atgatgtata aagctataca ttgtgttcaa 1080
aatatgaac cagaggagta tgctcataag attttggaat tacagatgca aagtataatg 1140
gaaaagaaaa tgaaaaccaa gagaaatatt gccaaagcatt acaagaataa cccatcacta 1200

```